QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) All Versions of this Article: jpet.106.110445v1 319/3/1286    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Allen, A. R. Articles by McDermott, B. J. Search for Related Content PubMed PubMed Citation Articles by Allen, A. R. Articles by McDermott, B. J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB (L)-ARGININE CALCIUM COMPOUNDS CALCIUM, ELEMENTAL

CARDIOVASCULAR

Modulation of Contractile Function through Neuropeptide Y Receptors during Development of Cardiomyocyte Hypertrophy

Cardiovascular Research Group, School of Medicine and Dentistry, Queen's University Belfast, Belfast, United Kingdom

Received July 6, 2006; accepted September 11, 2006.

	Abstract

Top Abstract Materials and Methods Results Discussion References

 
Severity of left ventricular hypertrophy (LVH) correlates with elevated plasma levels of neuropeptide Y (NPY) in hypertension. NPY elicits positive and negative contractile effects in cardiomyocytes through Y₁ and Y₂ receptors, respectively. This study tested the hypothesis that NPY receptor-mediated contraction is altered during progression of LVH. Ventricular cardiomyocytes were isolated from spontaneously hypertensive rats (SHRs) pre-LVH (12 weeks), during development (16 weeks), and at established LVH (20 weeks) and age-matched normotensive Wistar Kyoto (WKY) rats. Electrically stimulated (60 V, 0.5 Hz) cell shortening was measured using edge detection and receptor expression determined at mRNA and protein level. The NPY and Y₁ receptor-selective agonist, Leu³¹Pro³⁴NPY, stimulated increases in contractile amplitude, which were abolished by the Y₁ receptor-selective antagonist, BIBP3226 [R-N²-(diphenyl-acetyl)-N-(4-hydroxyphenyl)methyl-argininamide)], confirming Y₁ receptor involvement. Potencies of both agonists were enhanced in SHR cardiomyocytes at 20 weeks (2300- and 380-fold versus controls). Maximal responses were not attenuated. BIBP3226 unmasked a negative contraction effect of NPY, elicited over the concentration range (10^–12 to 3 x 10^–9 M) in which NPY and PYY_3–36 attenuated the positive contraction effects of isoproterenol, the potencies of which were increased in cardiomyocytes from SHRs at 20 weeks (175- and 145-fold versus controls); maximal responses were not altered. Expression of NPY-Y₁ and NPY-Y₂ receptor mRNAs was decreased (55 and 69%) in left ventricular cardiomyocytes from 20-week-old SHRs versus age-matched WKY rats; parallel decreases (32 and 80%) were observed at protein level. Enhancement of NPY potency, producing (opposing) contractile effects on cardiomyocytes together with unchanged maximal response despite reduced receptor number, enables NPY to contribute to regulating cardiac performance during compensatory LVH.

NPY can both decrease and increase the contractile response of electrically stimulated rat ventricular cardiomyocytes (Piper et al., 1989; Millar et al., 1991). The negative effect, observed in isoproterenol-treated cells, is due primarily to stimulation of the transient outward current (I_to) and mediated through an inhibitory G protein/adenylate cyclase pathway (Kassis et al., 1987; Piper et al., 1989; Millar et al., 1991). Use of the selective Y₂ receptor agonists, PYY_3–36 and NPY_13–36, inferred Y₂ receptor involvement (McDermott et al., 1997), but the finding that long C-terminal fragments of both PYY and NPY also exhibit high affinity for the Y₅ receptor subtype (Hu et al., 1996) emphasizes the need for clarification of receptor subtypes involved in NPY-stimulated cardiomyocyte contraction. NPY alone does not influence the basal level of contraction of cardiomyocytes, but in the presence of 4-aminopyridine, which selectively inhibits I_to in these cells, a positive response to NPY is unmasked (Millar et al., 1991). This has been observed also in chicken cardiomyocytes in the absence of rectifier current blockade (Jacques et al., 2000), and both effects are attributed to influx of Ca²⁺ via L-type channels and mediated through Y₁ receptor stimulation. Furthermore, Y₁ receptors are also coupled to mobilization of intracellular calcium stores in cardiomyocytes by a phospholipase C-dependent mechanism (Heredia et al., 2005).

The number of postsynaptic ₁-adrenoceptors and the amount of inositol 1,4,5-triphosphate accumulated in the myocardium in response to ₁-adrenoceptor stimulation are markedly increased in hypertension (Hanna and Khairallah, 1986). The release of NPY from the cardiac sympathetic innervation would also be expected to be enhanced during the pathogenesis of hypertension-induced myocardial hypertrophy; indeed, the plasma concentration (Zukowskagrojec et al., 1993; Bohm et al., 1995) and platelet content (Ogawa et al., 1992; Zukowskagrojec et al., 1993; Chen and Han, 1995) of NPY are increased, and alterations in NPY-mediated myocardial contractile responses may be anticipated because receptors for the peptide couple to signal transduction processes known to be altered in hypertrophied cardiomyocytes (Kawaguchi et al., 1992, 1993; Bohm et al., 1994; Cerbai et al., 1994; Xiao and McArdle, 1994; Yokoshiki et al., 1997).

The spontaneously hypertensive rat (SHR) is a useful model of pressure overload (Okamoto and Aoki, 1963; Pfeffer et al., 1976), in which hypertension, evident at 7 weeks of age, is followed by development of ventricular hypertrophy; a "hypertrophic window" at 12 to 20 weeks, which encompasses baseline and developmental characteristics at cardiomyocyte level, has been identified (Bell et al., 2004). Furthermore, the Y₅ receptor becomes coupled transiently to the stimulation of protein synthesis by NPY during the active phase of development of ventricular cell hypertrophy in the SHR, although receptor number is unaltered (Bell et al., 2002).

It was hypothesized that NPY receptor-mediated contraction responses become altered during progression of LVH. Focusing on the hypertrophic window above, effects on electrically stimulated contractile function were investigated in cardiomyocytes under basal conditions and when the cells were stimulated using Ca²⁺, the positive inotrope, isoproterenol, and NPY. In combination with Ca²⁺ or isoproterenol, use of selective NPY receptor agonists (Y₁ receptor, Leu³¹ Pro³⁴NPY; Y₂ receptor, PYY_3–36; Y₅ receptor, D-Trp³⁴NPY) and antagonists (Y₁ receptor, BIBP3226; Y₂ receptor, BIIE246) allowed differentiation of receptor-subtype mediated effects. Expression of NPY Y₁ and NPY Y₂ receptors was examined at mRNA and protein level.

	Materials and Methods

Top Abstract Materials and Methods Results Discussion References

 
Experimental Model. Male SHRs and age- and sex-matched Wistar Kyoto (WKY) normotensive rats were obtained from Harlan (Blackthorn, Oxon, UK) at 4 weeks of age and maintained at the Laboratory Service Unit (Queen's University Belfast, Belfast, UK) before sampling at 12, 16, and 20 weeks of age. The study was performed in accordance with the Home Office Guidance on the Operation of the Animals (Scientific Procedures) Act 1986, published by Her Majesty's Stationary Office (London, UK).

Isolation and Culture of Cardiomyocytes. After deep anesthesia of the rat using isoflurane (Abbott Laboratories, Kent, UK), the heart was excised quickly and placed in ice-cold 0.9% (w/v) NaCl. The heart was cannulated through the ascending aorta, and ventricular cardiomyocytes were isolated by the Langendorff retrograde perfusion method described previously (Bell et al., 2002). After purification, cells were suspended at a concentration of 1.5 x 10⁵ viable cardiomyocytes/ml in creatinine-carnitine-taurine medium.

Analysis of Contraction Function. An aliquot of myocyte suspension (150 µl) was placed in a transparent recording chamber mounted on an inverted phase-contrast microscope (Axiovert IM35; Carl Zeiss GmbH, Jena, Germany) and allowed to settle for 10 min before being bathed with oxygenated (95% O₂, 5% CO₂) Krebs-Henseleit buffer. Cells were field-stimulated at 0.5 Hz with biphasic pulses of 0.5-ms duration at 60 V via Ag/AgCl₂ wires embedded in the wall of the chamber. After initial stimulation, contractile amplitude was determined after incubation for 4 min (under basal conditions or with isoproterenol) or after 15 min (with NPY receptor agonists or antagonists). Responses to NPY receptor agonists were demonstrated in the presence of elevated Ca²⁺ (3 x 10^–3 M) or a submaximal concentration of isoproterenol (10^–8 M), as indicated. Concentration-effect relationships were obtained in a cumulative manner. The video edge detection equipment and the procedure used in the measurement of contraction amplitude were those described by Kelso et al. (2000).

Real-Time PCR. Total cellular RNA was isolated using acid guanidinium thiocyanate-phenol-chloroform extraction, and alterations in mRNA expression were determined by RT-PCR and expressed relative to glyceraldehyde-3-phosphate dehydrogenase mRNA. Reported sequences for each gene (Table 1) were used to design on Primer Express software (Applied Biosystems, Foster City, CA), rat-specific primers adapted to RT-PCR conditions, which were synthesized by Invitrogen (Carlsbad, CA). RT-PCR and subsequent analysis were performed as described previously (Zhao et al., 2006).

Immunodetection and Quantification of Membrane Protein. membranes were prepared from viable left ventricular cardiomyocytes as described previously (Zhao et al., 2006). Membrane protein concentration was determined by the method of Lowry. Protein samples were separated by 12% SDS-polyacrylamide gel electrophoresis (80 µg of protein per lane) as described previously (Zhao et al., 2006) and transferred to polyvinylidene difluoride membrane (0.45 µm; Millipore Corporation, Billerica, MA). The polyvinylidene difluoride membrane was washed with phosphate-buffered saline containing 0.1% (v/v) Tween 20 (Sigma Chemical Co. Ltd., Poole, Dorset, UK)) and blocked overnight in phosphate-buffered saline/0.1% (v/v) Tween 20 solution containing 5% (w/v) Marvel. Immunoblotting was performed using primary antibodies directed specifically against rodent NPY Y₁ and Y₂ receptors (Santa Cruz Biotechnology; sc-21992 and sc-14736, respectively, raised in goat) used at a dilution of 1:500. Immunocomplexes were detected using secondary antibodies conjugated to horseradish peroxidase (donkey anti-goat sc-2020 used at a dilution of 1:20,000; Santa-Cruz Biotechnology) and ECL plus (GE Healthcare, Little Chalfont, Buckinghamshire, UK) as substrate and quantified by densitometry (Analytical Imaging System) normalized for protein loading using -actin (Santa Cruz Biotechnology; sc-1616 raised in goat).

Chemicals. Medium M199 (glutamine-free with Earle's salts) and penicillin (5000 IU)/streptomycin (5 mg/ml) were supplied by Gibco BRL (Paisley, Renfrewshire, UK). Carnitine, creatine, taurine, 4-aminopyridine, isoproterenol hydrochloride, and BIBP3226 were obtained from the Sigma Chemical Co. Ltd. NPY (human, rat), Leu³¹Pro³⁴NPY (human, rat), and PYY_3–36 were purchased from Bachem (St. Helens, Merseyside, UK). BIIE246 was kindly supplied by Dr. Henri Doods (Boehringer Ingelheim Pharmaceuticals, Biberach, Germany). D-Trp³⁴NPY was synthesized in the laboratory of Professor Ambikaipakan Balasubramaniam (University of Cincinnati Medical Center, Cincinnati, OH). All other chemicals were of analytical grade and purchased from BDH Chemicals (Poole, Dorset, UK).

Solutions. Serum-free creatinine-carnitine-taurine medium consisted of modified glutamine-free medium M199 supplemented with Earle's salts and containing 15 mM HEPES, 5 mM creatine, 2 mM l-carnitine, 5 mM taurine, and 100 µg/ml penicillin/100 IU/ml streptomycin. The composition of the Krebs-Henseleit solution was 120 mM NaCl, 4.7 mM KCl, 25 mM NaHCO₃, 0.97 mM MgSO₄, 1.2 mM KH₂PO₄, 11 mM glucose, and 1 or 3 mM Ca²⁺. Before use, this solution was gassed with 95% O₂/5% CO₂ for 20 min and maintained at pH 7.4.

Data Analysis. All data are presented as mean ± S.E.M. Contraction amplitude was measured in micrometers and expressed as a percentage change from the diastolic length, as an absolute value (%L), or as a change from the baseline (%L), and n denotes the number of cell preparations used. Concentration-response data were analyzed by nonlinear regression using GraphPad Prism (version 4; GraphPad Software Inc., San Diego, CA). Statistical analyses were preformed by analysis of variance to detect significant differences for between-group (age, strain) or within-group (treatment) effects and post hoc comparisons by Bonferroni or an unpaired Student's t test as appropriate, using an SPSS package (version 11.5; SPSS Inc., Chicago, IL). Values of p < 0.05 were considered significant.

	Results

Top Abstract Materials and Methods Results Discussion References

 
Control Experiments for the Effect of NPY and Associated Compounds on Contractile Function. The following agonists had no effect per se with Ca²⁺ (10^–3 M) on contractile amplitude (L%) of cardiomyocytes (data are given as mean ± S.E.M. and were obtained in cardiomyocytes from 12-week-old animals following 15-min incubation with agonist versus time-matched baseline values): NPY (10^–7 M: 3.86 ± 0.86 versus 4.04 ± 0.35, n = 6 WKY; 3.38 ± 0.96 versus 3.98 ± 1.07, n = 6 SHR; 3 x 10^–9 M: 3.84 ± 0.50 versus 3.79 ± 0.75, n = 6 WKY; 2.00 ± 0.42 versus 1.56 ± 0.40, n = 6 SHR), Leu³¹Pro³⁴NPY (10^–7 M: 3.43 ± 0.66 versus 3.40 ± 0.57, n = 6 WKY; 2.84 ± 0.48 versus 3.19 ± 0.42, n = 6 SHR), PYY_3–36 (3 x 10^–9 M: 5.57 ± 1.69 versus 5.53 ± 1.68, n = 5 WKY; 2.83 ± 0.60 versus 2.79 ± 0.46, n = 6 SHR), and D-Trp³⁴NPY (10^–7 M: 1.00 ± 0.29 versus 1.25 ± 0.30, n = 5 WKY; 2.04 ± 0.26 versus 2.22 ± 0.21, n = 6 SHR). Likewise, there were no effects of the antagonists, BIBP3226 (10^–7 M: 4.19 ± 1.35 versus 4.29 ± 1.22, n = 4 WKY; 6.57 ± 1.01 versus 6.67 ± 1.18, n = 4 SHR) or BIIE246 (10^–7 M: 5.92 ± 1.38 versus 6.03 ± 1.06, n = 4 WKY; 3.26 ± 1.29 versus 3.37 ± 1.30, n = 4 SHR) per se with Ca²⁺ (10^–3 M); also BIIE246 (10^–7 M) did not antagonize the response to isoproterenol (10^–8 M) (4.79 ± 0.78 in the presence of BIIE246 versus 3.70 ± 0.63 alone, n = 4 WKY; 4.24 ± 0.56 in the presence of BIIE versus 3.63 ± 0.35 alone, n = 4 SHR). Therefore, BIBP3226 and BIIE246 can be used appropriately to test the Y₁ and Y₂ receptor subtype specificity, respectively, of NPY responses. Leu³¹Pro³⁴NPY (10^–7 M) with Ca²⁺ (10^–3 M) did not alter the positive effect of isoproterenol (10^–8 M) on amplitude of contraction (5.53 ± 0.41 in the presence of Leu³¹Pro³⁴NPY versus 5.46 ± 0.49 alone, n = 6 WKY; 4.40 ± 0.77 in the presence of Leu³¹Pro³⁴NPY versus 4.01 ± 0.58 alone, n = 4 SHR). Therefore, it is apparent that the Y₁ receptor-selective compound does not have activity at Y₂ receptors in this experimental system. For experiments with BIIE246, concentrations of NPY and PYY_3–36 that produced maximal attenuation of isoproterenol (10^–8 M)-stimulated contraction amplitude were initially determined because potency increased with increasing age of SHRs, the concentration used in 16- and 20-week-old rats was 3 x 10^–10 M but was 3 x 10^–9 M in 12-week-old SHRs and all WKY rats.

Receptor Subtype-Mediated Effects on Electrically Stimulated Contraction of Rat Cardiomyocytes. Data obtained in our laboratory establishing the temporal development of hypertension and cardiomyocyte hypertrophy in SHRs during the period 12 to 20 weeks employed in the contraction experiments below have been published previously (Bell et al., 2004).

Temporal and Concentration Dependence of the Positive Contraction Response. A representative original tracing of the stimulation of contractile activity by NPY is shown in Fig. 1a. In the presence of Ca²⁺ (3 x 10^–6 M), NPY (Fig. 2a) and Leu³¹Pro³⁴NPY (Fig. 2b) stimulated concentration-dependent increases in contraction amplitude in cardiomyocytes from SHRs and WKY rats of all ages. At 12 weeks, increases were observed in the range, 10^–10 to 10^–7 M, and EC₅₀ values (in the 10^–9 M range) were similar. The potency of NPY was unaltered with the progression of age in WKY rat cardiomyocytes but significantly increased in cardiomyocytes from 20-week-old SHRs (2500- and 2800-fold greater than observed at 12 and 16 weeks of age, respectively). Age-matched between-strain comparisons showed that the potency of NPY was significantly elevated at 20 (2300-fold) but not at 12 and 16 weeks of age in cardiomyocytes from SHRs. Comparison of the effects of NPY and Leu³¹Pro³⁴NPY with increased contraction amplitude showed that the potencies were similar under all conditions. As such, the potency of Leu³¹Pro³⁴NPY to increase contraction amplitude was unchanged in WKY rat cardiomyocytes but enhanced in cardiomyocytes obtained from SHRs at 20 weeks of age (380-fold versus age-matched controls). Maximal responses to NPY and to Leu³¹Pro³⁴NPY did not differ significantly between SHR and WKY rats at any age. The Y₁ receptor-selective antagonist, BIBP3226, abolished the positive contraction effects of NPY (Fig. 3a) and Leu³¹Pro³⁴NPY (Fig. 3b) across the range of concentration used (10^–13 to 10^–7 M) in both SHR and WKY rat cardiomyocytes at all ages.

View larger version (13K): [in this window] [in a new window]   Fig. 1. Example recordings of positive contractile effect of NPY (10–7 M) (a) and negative contractile effect of NPY (10–9 M) on elevated response to isoproterenol (ISO; 10–8 M) (b) in electrically stimulated cardiomyocytes.

View larger version (23K): [in this window] [in a new window]   Fig. 2. Effects of NPY (a) and Leu31Pro34NPY (b) in the presence of Ca2+ (3 x 10–6 M) to stimulate contraction amplitude of cardiomyocytes from WKY rats and SHRs at 12 (i), 16 (ii), and 20 (iii) weeks of age. Data are given as differences from basal value, expressed as a percentage of resting cell length (L%) and are mean values + S.E.M. of n = 5 to 6 experiments. EC50 values (in moles per liter) are: a, (5.1 ± 3.2) x 10–10, (7.2 ± 6.5) x 10–10, and (1.1 ± 0.5) x 10–9, in WKY rats and (1.2 ± 0.22) x 10–9, (1.3 ± 0.5) x 10–9, and (4.8 ± 1.1) x 10–13* in SHRs; and b, (9.2 ± 4.8) x 10–10, (3.1 ± 6.5) x 10–10, (2.3 ± 0.9) x 10–10 in WKY rats; and (4.4 ± 2.0) x 10–10, (1.2 ± 0.3) x 10–9, (6.0 ± 4.8) x 10–13* in SHRs, respectively. *, p < 0.05 versus strain-matched 12-week-old rats; , p < 0.05 versus strain-matched 16-week-old rats; , p < 0.05 versus age-matched WKY rats.

View larger version (23K): [in this window] [in a new window]   Fig. 3. Effect of the Y1 receptor-selective antagonist, BIBP3226 (10–7 M), on amplitude of contraction stimulated by NPY (a) and Leu31Pro34NPY (b) in the presence of Ca2+ (3 x 10–6 M) in cardiomyocytes from WKY rats and SHRs at 12 (i), 16 (ii), and 20 (iii) weeks of age Data are given as differences from basal value, expressed as a percentage of resting cell length (L%), and are mean values + S.E.M. of n = 6 experiments. EC50 values (in moles per liter) are: a, (6.0 ± 2.7) x 10–10, (6.7 ± 2.6) x 10–10, and (7.9 ± 2.6) x 10–11 in WKY rats and (1.9 ± 0.69) x 10–10, (1.0 ± 0.5) x 10–9, and (1.4 ± 0.67) x 10–12* in SHRs, respectively. *, p < 0.05 versus strain-matched 12-week-old rats; , p < 0.05 versus age-matched WKY rats.

Temporal and Concentration Dependence of the Negative Contraction Response to NPY Unmasked in the Presence of BIBP3226. NPY in the presence of BIBP3226 elicited a negative, concentration-dependent effect in all cases (Fig. 3a), observed over the same range of concentration in which application of NPY alone had increased contraction amplitude in the presence of Ca²⁺ (3 x 10^–6 M) (Fig. 2a). In cardiomyocytes from SHRs and WKY rats at 12 weeks of age, decreases in contraction amplitude stimulated by NPY in the presence of BIBP3226 had similar EC₅₀ values (in the 10^–10 M range). In WKY rat cardiomyocytes, the EC₅₀ value was unaltered with increasing age but in SHR cardiomyocytes, increased significantly at 20 weeks of age (100- to 800-fold greater than observed at 12 and 16 weeks of age). In age-matched comparisons between strains, the potency value in SHR cardiomyocytes was significantly altered compared with that observed in cardiomyocytes from WKY rats at 20 but not at 12 and 16 weeks of age. In the presence of BIBP3226, Leu³¹Pro³⁴NPY applied over the same concentration range, which, when used alone, had increased contraction amplitude in SHR and WKY rat cardiomyocytes, had no effect on amplitude of contraction (Fig. 3b).

Temporal and Concentration Dependence of the Negative Contraction Response to PYY_3–36 Alone. PYY_3–36 (10^–12 to 3 x 10^–9 M) elicited a concentration-dependent, negative contraction effect in cardiomyocytes from SHRs and WKY rats of all ages (Fig. 4). Maximal responses to PYY_3–36 did not differ significantly between SHR and WKY rats at any age. The potency of PYY_3–36 was similar in cardiomyocytes from 12-week-old rats of each strain, in the region of 3 x 10^–10 M, and in WKY rat cardiomyocytes was unchanged with progression of age, whereas potency increased in SHRs, becoming significantly elevated (x400) in cardiomyocytes from 20-compared with 12-week-old rats. The potency of PYY_3–36 was similar in cardiomyocytes from age-matched 12-week-old SHRs and WKY rats but was noticeably increased (x10) at 16 weeks, becoming significantly elevated (x400) in cardiomyocytes from 20-week-old SHRs compared with that found in WKY rats. The potencies of PYY_3–36 and NPY in the presence of BIBP3226 (Figs. 4 and 3, respectively) under any condition were not different.

View larger version (14K): [in this window] [in a new window]   Fig. 4. Effect of PYY3–36 in the presence of Ca2+ (3 x 10–6 M) to attenuate contraction amplitude of cardiomyocytes from WKY rats and SHRs at 12 (a), 16 (b), and 20 (c) weeks of age. Data are given as differences from basal value, expressed as a percentage of resting cell length (L%), and are mean values + S.E.M. of n = 6 experiments. EC50 values (in moles per liter) are: (2.2 ± 0.71) x 10–10, (1.7 ± 0.98) x 10–10, and (2.1 ± 0.31) x 10–10 in WKY rats and (3.2 ± 1.8) x 10–10, (2.5 ± 0.29) x 10–11, and (7.5 ± 4.5) x 10–13* in SHRs, respectively. *, p < 0.05 versus strain-matched 12-week-old rats; , p < 0.05 versus strain-matched 16-week-old rats; , p < 0.05 versus age-matched WKY rats.

View larger version (29K): [in this window] [in a new window]   Fig. 5. Attenuation of isoproterenol (10–8 M)-stimulated contraction amplitude by NPY (a) and PYY3–36 (b) under conditions of physiological Ca2+ concentration (10–3 M) in cardiomyocytes from WKY rats (i) and SHRs (ii) at 12, 16, and 20 weeks of age. Data are given as percentage inhibition of the isoproterenol response and are mean values + S.E.M. of n = 8 experiments. EC50 values (in moles per liter) are: a, (5.8 ± 1.1) x 10–10, (2.8 ± 0.64) x 10–10, and (7.5 ± 2.9) x 10–10 in WKY rats and (2.4 ± 2.2) x 10–10, (6.1 ± 0.70) x 10–11, and (4.3 ± 3.7) x 10–12* in SHRs; b, (8.8 ± 6.7) x 10–10, (1.3 ± 1.7) x 10–9, and (6.1 ± 0.60) x 10–10 in WKY rats and (1.6 ± 0.66) x 10–10, (2.7 ± 0.41) x 10–11, and (4.2 ± 1.1) x 10–12* in SHRs; respectively. *, p < 0.05 versus strain-matched 12-week-old rats; , p < 0.05 versus age-matched WKY rats.

View larger version (21K): [in this window] [in a new window]   Fig. 6. Effect of the Y2 receptor-selective antagonist, BIIE246 (10–7 M) [n = 6], on maximal NPY (a)- and PYY(b) -induced attenuation of isoproterenol (10–8 M)-stimulated amplitude of contraction in cardiomyocytes using the peptides at a maximally effective concentration of 3 x 10–9 M in WKY rats at all ages and in 12-week-old SHRs and at 3 x 10–10 M in 16- and 20-week-old SHRs to take account of increased potency of the peptides with advancing age in SHRs. Data are expressed as a percentage of the control isoproterenol response and are mean values + S.E.M. of n = 8 experiments.

Gene Expression of NPY and Receptors. NPY-Y₁ receptors were expressed more abundantly than NPY-Y₂ receptors at mRNA and protein levels in left ventricular cardiomyocytes from WKY rats at 20 weeks of age (Fig. 7). Expression of NPY-Y₁ and NPY-Y₂ receptor mRNAs was decreased by 55 (p < 0.05) and 69% (p < 0.05), respectively, in left ventricular cardiomyocytes from 20-week-old SHRs relative to that of age-matched WKY rats; parallel decreases of 32 (p = N.S.) and 80% (p < 0.05), respectively, were observed at the protein level.

View larger version (30K): [in this window] [in a new window]   Fig. 7. NPY-Y1 and NPY-Y2 receptor mRNA RT-PCR dissociation curves (a), cyclic numbers (b), and expression levels standardized to GADPH mRNA (c and d); representative immunoblots and receptor protein levels standardized to -actin (e and f) in left ventricular cardiomyocytes isolated from SHR and WKY rats aged 20 weeks. Data are mean values + S.E.M. of n = 7 to 9 experiments. *, p < 0.05 versus age-matched WKY rats.

	Discussion

Top Abstract Materials and Methods Results Discussion References

Altered Potency at NPY Receptors during the Development of Hypertrophy. Under normal conditions when hypertensive disease is absent, the positive contraction effect of NPY was maintained at a constant level. This may arise because in the absence of pressure overload, there is no need to potentiate the contraction performance of cardiomyocytes. Plasma levels of circulating NPY in WKY rats are approximately 4 x 10^–11 M (Ogawa et al., 1989), which lies just outside the range (10^–10 to 10^–7 M) in which the peptide stimulates increased contraction function in WKY rat myocytes. Therefore, it seems that modulation of contraction function by NPY is a redundant mechanism in normotensive animals. The SHR myocardium could undergo a stress-induced change in which the importance of peptidic regulation of function is of greater importance. The NPY level in SHR plasma (Ogawa et al., 1989) would certainly stimulate the maximal positive contraction effect of the peptide in 20-week-old SHR cardiomyocytes. Therefore, the hypertrophied myocardium may adapt so that NPY may play a part in the modulation of contractile function via Y₁ receptors. Likewise, the concentration range (10^–10 to 3 x 10^–9 M) in which NPY (and PYY_3–36) stimulated their negative contraction effects in WKY rat myocytes is less than the in vivo plasma concentration of NPY (Ogawa et al., 1989). Therefore, the Y₂ receptor-mediated negative contraction effect may also be a redundant mechanism in normotensive animals. However, the potency of both peptides to elicit this negative effect was up-regulated in cardiomyocytes from 20-week-old SHRs to a level at which the observed circulatory concentration of NPY would be expected to elicit a maximal negative effect. Again, this is consistent with the hypothesis that in hypertensive disease, peptidic regulation of the myocardium is enhanced. Augmented activity of the sympathetic neurotransmitter norepinephrine (possibly in combination with NPY acting via Y₁ receptors) would promote myocardial contractility during systole and help initially to maintain cardiac output despite increased after-load, working alongside the progressive unloading of muscle fibers achieved by the more gradual development of compensatory LVH in an attempt to normalize wall stress. However, prolonged activation of sympathetic drive would be expected to increase myocardial oxygen demand and energy expenditure of the hypertrophied myocardium, thereby contributing to cardiomyocyte ischemia and eventually cell death due to apoptosis or necrosis, resulting in impaired contractility of the residual myocardium and reduced ability to sustain the increased load because adult cardiomyocytes have only limited potential for self-renewal (Anversa et al., 2006). Enhancement of the negative contraction effect of NPY during early compensated hypertensive LVH could therefore represent a protective measure to help to counter the excessive shortening and energy expenditure of cardiomyocytes in response to norepinephrine. However, impaired intrinsic myocardial contractility has also been observed in patients with prolonged hypertension despite fully compensated ventricular hypertrophy, normal wall stress, and apparently normal pump function (Aoyagi et al., 1993). The possibility should be considered that chronic enhancement of the negative contraction effects of NPY could instead represent a pathophysiological phenomenon, such that sustained depression of contractility mediated via Y₂ receptor stimulation may exacerbate progressive mechanical dysfunction and impair ventricular emptying during systole and ultimately accelerate transition to overt failure.

Reduced NPY Receptor Numbers in Established Cardiomyocyte Hypertrophy. Decreased Y₂ and, to a lesser extent, Y₁ receptor numbers in SHR cardiomyocytes at 20 weeks might reflect receptor down-regulation that could arise by negative feedback as a consequence of increased receptor activity in SHR due to the observed increased potency of agonist-receptor complex interactions. However, maximal contractile responses to NPY and receptor subtypeselective antagonists were not reduced significantly, indicating either that residual receptor numbers are probably still surplus to functional requirements or that up-regulation of downstream signaling components coupled to Y receptors might offset any consequences of reduced receptor number. In regard to the latter, phospholipase C--mediated mobilization of intracellular calcium stores is enhanced in SHR myocardium (Kawaguchi et al., 1992, 1993). Because Y₁ receptors are known to couple to mobilization of intracellular calcium stores in cardiomyocytes by a phospholipase C-dependent mechanism (Heredia et al., 2005), enhanced activity downstream of the receptor-involvement could compensate for, or alternatively may contribute to, recruitment of processes responsible for the modest reduction in Y₁ receptor number. Expression of G_i- subunit protein is also enhanced, and G_i-mediated inhibition of adenylate cyclase is augmented (Bohm et al., 1994), implying enhanced activity downstream of the Y₂ receptor. Again, this could compensate for, or alternatively may contribute to, the regulation of processes responsible for the modest reduction in Y₂ receptor number. However, I_to current is blunted (Cerbai et al., 1994; Yokoshiki et al., 1997); conversely, L-type calcium channel current is enhanced (Xiao and McArdle, 1994) in hypertrophied SHR myocardium. These effects would oppose the negative contraction effect of NPY, mediated via the Y₂ receptor subtype. This observation, together with the greater reduction in Y₂ than Y₁ receptor protein in hypertrophied cardiomyocytes, indicates that the balance between the opposing actions of the peptide may shift toward the Y₁-mediated positive contractile response to assist the myocardium in potentiation of normal contractile performance and attempt to offset a potentially detrimental influence of Y₂ receptor stimulation.

Future Studies and Clinical Significance. The sympathetic nervous system cotransmitter, NPY, can elicit in SHR cardiomyocytes, an increase in the amplitude of contraction through the Y₁ receptor subtype, and also a negative effect on contraction parameters through the Y₂ receptor subtype, which both involve modulation of intracellular Ca²⁺ signaling. The potency of NPY to elicit positive and negative contraction effects is dramatically increased during the established phase of hypertrophic growth. As a compensatory strategy, the positive effect of NPY may contribute to maintenance of normal circulatory function, at least initially, in hypertension, whereas the negative contraction effect may contribute to the pathophysiological changes occurring within the myocardium, which ultimately contribute to the transition to overt failure. This study has focused on the early phase of compensated LVH in the SHR. Clearly, it would now be important to explore NPY-mediated contraction responses in aged SHR during the transition into overt failure to determine whether the alterations identified in regard to each NPY receptor subpopulation persist and are enhanced. To further elucidate the respective roles of pressure loading and LVH on the changes observed, parallel studies in an appropriate model of volume-overload LVH should also be conducted. Intervention with suitable Y₂-selective antagonists in SHRs in vivo together with transgenic overexpression or knockout of the Y₂ receptor in aortic banded mice should help to clarify whether the influence of this receptor is cardioprotective or ultimately detrimental in the setting of pressure overload and, provided such findings can be extrapolated to humans, might indicate the rationale for therapeutic intervention with agents targeting this receptor subpopulation.

	Footnotes

 
This work was supported by the British Heart Foundation.

Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

doi:10.1124/jpet.106.110445.

ABBREVIATIONS: NPY, neuropeptide Y; LVH, left ventricular hypertrophy; SHR, spontaneously hypertensive rat; BIBP3226, R-N²-(diphenylacetyl)-N-(4-hydroxyphenyl)methyl-argininamide); BIIE246, (S)-N²-([1-{2-(4-[(r,s)-5,11-dihydro-6(6H)-oxodibenz(b,e)azepin-11-yl]-1-piperazinyl)-2-oxoethyl}cyclopentyl]acetyl)-N-(2-[1,2-dihydro-3,5(4H)-dioxo-1,2-diphenyl-3H-1,2,4-triazol-4-yl]ethyl)-argininamide; WKY, Wistar Kyoto; PCR, polymerase chain reaction; RT, reverse transcriptase.

Address correspondence to: Dr. David Bell, Division of Medicine and Therapeutics, Whitla Medical Building, 97 Lisburn Road, Belfast BT9 7BL, UK. E-mail: d.bell{at}qub.ac.uk

	References

Top Abstract Materials and Methods Results Discussion References

 

Agabiti-Rosei E and Muiesan ML (2001) Hypertensive left ventricular hypertrophy: patho-physiological and clinical issues. Blood Pressure 10: 288–298.[CrossRef][Medline]

Allen JM, Gjorstrup P, Bjorkman JA, Ek L, Abrahamsson T, and Bloom SR (1986) Studies on cardiac distribution and function of neuropeptide Y. Acta Physiol Scand 126: 405–411.[Medline]

Anversa P, Leri A, and Kajstura J (2006) Cardiac regeneration. J Am Coll Cardiol 47: 1769–1776.[Abstract/Free Full Text]

Aoyagi T, Fujii AM, Flanagan MF, Arnold LW, Brathwaite KW, Colan SD, and Mirsky I (1993) Transition from compensated hypertrophy to intrinsic myocardial dysfunction during development of left ventricular pressure-overload hypertrophy in conscious sheep: systolic dysfunction precedes diastolic dysfunction. Circulation 88: 2415–2425.[Abstract/Free Full Text]

Bell D, Allen AR, Kelso EJ, and McDermott BJ (2002) Induction of hypertrophic responsiveness to neuropeptide Y is mediated by the cardiomyocyte Y₅ receptor in the spontaneously hypertensive rat. J Pharmacol Exp Ther 303: 581–591.[Abstract/Free Full Text]

Bell D, Lee GR, Kelso EJ, Allen AR, and McDermott BJ (2004) Temporal dependence of the onset of parameters of cardiomyocyte hypertrophy in response to pressure overload in the spontaneously hypertensive rat. Cardiovasc Pathol 13: 71–78.[Medline]

Bohm M, Castellano M, Paul M, and Erdmann E (1995) Cardiac noradrenaline, b-adrenoceptors and G_i proteins in prehypertensive and hypertensive spontaneously hypertensive rats. J Cardiovasc Pharmacol 23: 980–987.

Bohm M, Grabel C, Knorr A, and Erdmann E (1994) Treatment in hypertensive cardiac hypertrophy 1: NPY and beta-adrenoceptors. Hypertension 25: 954–961.

Cerbai E, Barbieri M, Li Q, and Mugelli A (1994) Ionic basis of action potential prolongation of hypertrophied cardiac myocytes from hypertensive rats of different ages. Cardiovasc Res 28: 1180–11087.[Abstract/Free Full Text]

Chen SH and Han QD (1995) Increase of release of NPY in vitro from platelets of spontaneously hypertensive rats. Acta Pharmacol Sin 16: 149–151.

Doods H, Gaida W, Wieland HA, Dollinger H, Schnorrenberg G, Esser F, Engel W, Eberlein W, and Rudolf K (1999) BIIE0246: a selective and high affinity neuropeptide Y Y(2) receptor antagonist. Eur J Pharmacol 384: R3–R5.[CrossRef][Medline]

Doods HN, Wieland HA, Engel W, Eberlein W, Willim KD, Entzeroth M, Wienen W, and Rudolf K (1996) BIBP3226, the first selective neuropeptide Y₁ receptor antagonist: a review of its pharmacological properties. Regul Peptides 65: 71–77.[CrossRef][Medline]

Franco-Cereceda A, Lundberg JM, and Dahlof C (1985) Neuropeptide Y and sympathetic control of heart contractility and coronary vascular tone. Acta Physiol Scand 124: 361–369.[Medline]

Grandt D, Schimiczek M, Rascher W, Feth F, Shively J, Lee TD, Davis MT, Reeve JRJ, and Michel MC (1996) Neuropeptide Y 3–36 is an endogenous ligand selective for Y2 receptors. Regul Peptides 67: 33–37.[CrossRef][Medline]

Hanna MK and Khairallah PA (1986) Alterations of myocardial alpha-1 adrenergic receptors in hypertensive cardiac hypertrophy of the rat. Arch Int Pharmacodyn Ther 283: 80–93.[Medline]

Heredia M del P, Delgado C, Pereira L, Perrier R, Richard S, Vassort G, Benitah J-P and Gomez AM (2005) Neuropeptide Y rapidly enhances calcium transients and calcium sparks in adult rat ventricular myocytes through Y receptor and PLC activation. J Mol Cell Cardiol 38: 205–212.[CrossRef][Medline]

Hu Y, Bloomquist BT, Cornfield LJ, DeCarr LB, Flores-Riveros JR, Friedman L, Jiang P, Lewis-Higgins L, Sadlowski Y, Schaefer J, et al. (1996) Identification of a novel hypothalamic neuropeptide Y receptor associated with feeding behavior. J Biol Chem 271: 26315–26319.[Abstract/Free Full Text]

Hulting J, Sollevi A, Ullman B, Franco-Cereceda A, and Lundberg JM (1990) Plasma neuropeptide Y on admission to a coronary care unit: raised levels in patients with left heart failure. Cardiovasc Res 24: 102–108.[Abstract/Free Full Text]

Jacques D, Sader S, El-Bizri N, Chouffani S, Hassan G, and Shbaklo H (2000) Neuropeptide Y induced increase of cytosolic and nuclear Ca²⁺ in heart and vascular smooth muscle cells. Can J Physiol Pharmacol 78: 162–172.[CrossRef][Medline]

Kassis S, Olasmaa M, Terenius L, and Fishman PH (1987) Neuropeptide Y inhibits cardiac adenylate cyclase through a pertussis toxin-sensitive G-protein. J Biol Chem 262: 3429–3431.[Abstract/Free Full Text]

Kawaguchi H, Sano H, Okada H, Iizuka K, Okamoto H, Kudo T, Murakami T, and Kitabatake A (1993) Increased calcium release from SR stimulated by IP₃ in SHR cells. Mol Cell Biochem 119: 51–57.[CrossRef][Medline]

Kawaguchi H, Shoki M, Sano H, Kudo T, Sawa H, Mochizuki N, Okamato H, Endo Y, and Kitabatake A (1992) PI metabolism in hypertrophied rat heart. J Mol Cell Cardiol 24: 1003–1010.[CrossRef][Medline]

Kelso E, McDermott B, Silke B, and Spiers JP (2000) Positive effect of bumetanide on contractile activity of ventricular cardiomyocytes. Eur J Pharmacol 400: 43–50.[CrossRef][Medline]

Maisel AS, Scott NA, Motulsky HJ, Michel MC, Boublik JH, Rivier JE, Ziegler M, Allen RS, and Brown MR (1989) Elevation of plasma neuropeptide Y levels in congestive heart failure. Am J Med 86: 43–48.[CrossRef][Medline]

McDermott BJ, Millar BC, Dolan FM, Bell D, and Balasubramaniam A (1997) Evidence for Y₁ and Y₂ subtypes of neuropeptide Y receptors linked to opposing postjunctional effects observed in rat cardiac myocytes. Eur J Pharmacol 336: 257–265.[CrossRef][Medline]

Millar BC, Piper HM, and McDermott BJ (1988) The antiadrenergic effect of neuropeptide Y on the ventricular cardiomyocyte. N-S Arch Pharmacol 338: 426–429.

Millar BC, Weis T, Piper HM, Weber M, Borchard U, McDermott BJ, and Balasubramaniam A (1991) Positive and negative contraction effects of neuropeptide Y on ventricular cardiomyocytes. Am J Physiol 261: H1727–H1733.

Ogawa T, Kitamura K, Kawamoto M, Eto T, and Tanaka K (1989) Increased immunoreactive neuropeptide Y in platelets of spontaneously hypertensive rats (SHR). Biochem Biophys Res Commun 165: 1399–1405.[CrossRef][Medline]

Ogawa T, Kitamura K, Kangawa K, Matsuo H, and Eto T (1992) Platelet NPY in spontaneously hypertensive rats. J Hypertension 10: 765–771.[Medline]

Okamoto K and Aoki K (1963) Development of a strain of spontaneously hypertensive rats. Jpn Circ J 27: 282–293.[Medline]

Onuoha GN, Nicholls DP, Alpar EK, Ritchie A, Shaw C, and Buchanan K (1999) Regulatory peptides in the heart and major vessels of man and mammals. Neuropeptides 33: 165–172.[CrossRef][Medline]

Pfeffer MA, Pfeffer JM, and Frohlich D (1976) Pumping ability of the hypertrophying left ventricle of the spontaneously hypertensive rat. Circ Res 38: 423–429.[Abstract/Free Full Text]

Piper HM, Millar BC, and McDermott BJ (1989) The negative inotropic effect of neuropeptide Y on the ventricular cardiomyocyte. Naunyn-Schmiedeberg's Arch Pharmacol 340: 333–337.[Medline]

Xiao YF and McArdle JJ (1994) Elevated density and altered pharmacologic properties of myocardial calcium current of the spontaneously hypertensive rat. J Hypertension 12: 783–790.[Medline]

Yokoshiki H, Kohya T, Tomita F, Tohse N, Nakaya H, Kanno M, and Kitabatake A (1997) Restoration of action potential duration and transient outward current by regression of left ventricular hypertrophy. J Mol Cell Cardiol 29: 1331–1339.[CrossRef][Medline]

Zhao YY, Bell D, Smith LR, Zhao L, Devine AB, McHenry EM, Nicholls DP, and McDermott BJ (2006) Differential effects of components of the cardiomyocyte adrenomedullin/intermedin receptor system following blood pressure reduction in nitric oxide-deficient hypertension. J Pharmacol Exp Ther 316: 1269–1281.[Abstract/Free Full Text]

Zukowskagrojec ZG, Olczyska M, Shen GH, Torresduarte A, Haass M, Wahlestedt C, and Myers AK (1993) Modulation of vascular function by neuropeptide Y during development of hypertension in spontaneously hypertensive rats. Pediatr Nephrol 7: 845–852.[CrossRef][Medline]

This Article Abstract Full Text (PDF) All Versions of this Article: jpet.106.110445v1 319/3/1286    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Allen, A. R. Articles by McDermott, B. J. Search for Related Content PubMed PubMed Citation Articles by Allen, A. R. Articles by McDermott, B. J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB (L)-ARGININE CALCIUM COMPOUNDS CALCIUM, ELEMENTAL